Response-guided telaprevir combination treatment for hepatitis C virus infection

New England Journal of Medicine

Volumn 365, Issue 11, 2011, Pages 1014-1024

  Sherman, Kenneth E ^a   Flamm, Steven L ^b   Afdhal, Nezam H ^c   Nelson, David R ^d   Sulkowski, Mark S ^e   Everson, Gregory T ^f   Fried, Michael W ^g   Adler, Michael ^h   Reesink, Hendrik W ⁱ   Martin, Marie ^j   Sankoh, Abdul J ^j   Adda, Nathalie ^j   Kauffman, Robert S ^j   George, Shelley ^j   Wright, Christopher I ^j   Poordad, Fred ^k  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h ERASME HOSPITAL   (Belgium)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j VERTEX PHARMACEUTICALS   (United States)

^k CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; GLUCOCORTICOID; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INJURY; INSOMNIA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; NAUSEA; NUTRITIONAL DISORDER; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; THORAX DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 80052826527     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1014463     Document Type: Article

References (11)

1. Hepatitis C. Geneva: World Health Organization, 2011. (http://www.who.int/vaccine-research/diseases/hepatitis-c/en/.)
2. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87. (Pubitemid 46453759)
3. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
6. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
7. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38. [Erratum, N Engl J Med 2009;361:1516.]
8. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-6.
9. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9. (Pubitemid 47436107)
10. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype1. Gastroenterology 2006;131:470-7. (Pubitemid 44142464)
11. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010;52:Suppl 1:436A. abstract.